# A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

> **NCT07066397** · PHASE1 · RECRUITING · sponsor: **TriArm Therapeutics (Taiwan) Limited** · enrollment: 12 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** ARM011
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07066397
- **Lead sponsor:** TriArm Therapeutics (Taiwan) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2028-04-01
- **Final completion:** 2041-04-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07066397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07066397, "A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07066397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*